Anmeldung erfolgt in Kürze...
Details werden geladen...
Tarlatamab Maintenance Combo Boosts Lung Cancer Survival
Loud applause followed the presentation of findings of the open-label DeLLphi-305 randomized clinical trial.
Ähnliche Seiten
Tambotatug Pelitecan Boosts Survival in Relapsed SCLC
https://www.medscape.com/viewarticle/tambotatug-pelitecan-boosts-survival-relapsed-sclc-2026a10010a1Lung Cancer in Teenagers: The Physicians’ Perspective
https://www.medscape.com/viewarticle/lung-cancer-teenagers-what-are-challenges-physicians-2026a10013krImmunotherapy Plus Radiotherapy Linked to Higher OS in NSCLC
https://www.medscape.com/viewarticle/immunotherapy-plus-radiotherapy-linked-higher-os-than-2026a10010ixDivarasib Beats Approved KRAS Inhibitors in Lung Cancer
https://www.medscape.com/viewarticle/divarasib-beats-approved-kras-inhibitors-lung-cancer-2026a10014jmNew Cancer Drugs: Can Care Keep Up With Innovation?
https://www.medscape.com/viewarticle/new-cancer-drugs-can-care-keep-innovation-2026a10010g7